Oramed Pharmaceuticals Inc.
ORMP · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $93,923 | $88,230 | $96,605 | $99,788 |
| - Cash | $15,797 | $74,516 | $54,420 | $42,104 |
| + Debt | $912 | $301 | $372 | $429 |
| Enterprise Value | $79,038 | $14,015 | $42,557 | $58,113 |
| Revenue | $0 | $2,000 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Gross Profit | -$30 | $13 | -$31 | $0 |
| % Margin | – | 0.7% | – | – |
| EBITDA | $13,164 | -$4,470 | -$9,752 | -$3,037 |
| % Margin | – | -223.5% | – | – |
| Net Income | $13,288 | -$7,642 | -$10,189 | -$19,619 |
| % Margin | – | -382.1% | – | – |
| EPS Diluted | 0.31 | -0.19 | -0.26 | -0.48 |
| % Growth | 263.2% | 26.9% | 45.8% | – |
| Operating Cash Flow | -$3,535 | -$3,519 | -$1,911 | -$7,101 |
| Capital Expenditures | -$4 | -$3 | -$11 | -$5 |
| Free Cash Flow | -$3,539 | -$3,522 | -$1,922 | -$7,106 |